111 Capital’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
Other funds holding REGN
111 Capital's REGN Position: Q2 2026 in Review
111 Capital increased its Regeneron Pharmaceuticals (REGN) stake by 243% in Q2 2026, buying an estimated $1.54M and bringing the position to 3,185 shares worth $1.99M. The position accounts for 0.34% of the portfolio, ranked #58.
111 Capital first reported a position in REGN in Q4 2024 and has held it in 6 quarters since. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- 111 Capital held 3,185 shares of Regeneron Pharmaceuticals worth $1.99M as of Q2 2026.
- 111 Capital bought 2,256 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $1.54M.
- Regeneron Pharmaceuticals made up 0.34% of 111 Capital's portfolio in Q2 2026, its #58 holding.
- 111 Capital first reported a position in Regeneron Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
- 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on 111 Capital's 13F filing for Q2 2026, filed 5 Aug 2026.